Relmada Therapeutics Stock Investor Sentiment

RLMD Stock  USD 3.29  0.27  8.94%   
About 70 percent of all Relmada Therapeutics' shareholders are curious in acquiring. The analysis of overall sentiment of trading Relmada Therapeutics stock suggests that quite a large number of investors are confidant at this time. The current market sentiment, together with Relmada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Relmada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Relmada Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Relmada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at accesswire.com         
Potential Securities Violations By Relmada Therapeutics Inc Are Under Investigation By The Schall La...
news
over three months ago at simplywall.st         
Institutional investors are Relmada Therapeutics, Inc.s biggest bettors and were rewarded after last...
Simply Wall St News at Macroaxis
over three months ago at accesswire.com         
Relmada Therapeutics Inc Under Scrutiny By The Schall Law Firm For Potential Securities Breaches Urg...
news
over three months ago at finance.yahoo.com         
Institutional investors have a lot riding on Relmada Therapeutics, Inc. with 48 percent ownership
Yahoo News
over three months ago at accesswire.com         
Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Viola...
news
over three months ago at accesswire.com         
Relmada Therapeutics Inc Is Being Probed By The Schall Law Firm For Potential Securities Breaches An...
news
over three months ago at accesswire.com         
Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Viola...
news
over three months ago at accesswire.com         
The Schall Law Firm Begins Probe Into Relmada Therapeutics Inc For Suspected Securities Violations A...
news
over three months ago at accesswire.com         
Investigation Into Possible Securities Infringements By Relmada Therapeutics Inc Is Being Conducted ...
news
over three months ago at accesswire.com         
The Schall Law Firm Initiates Examination Into Relmada Therapeutics Inc For Potential Securities Bre...
news
over three months ago at accesswire.com         
The Schall Law Firm Investigates Relmada Therapeutics Inc For Potential Securities Breaches And Enco...
news
over three months ago at accesswire.com         
The Schall Law Firm Probes Relmada Therapeutics Inc For Possible Securities Violations And Urges Aff...
news
over three months ago at accesswire.com         
The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Infringements Of Securit...
news
over three months ago at accesswire.com         
The Schall Law Firm Is Probing Relmada Therapeutics Inc For Possible Breaches Of Securities Laws And...
news
over three months ago at news.google.com         
Relmada Therapeutics, Inc. is favoured by institutional owners who hold 52 percent of the company - ...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Relmada Therapeutics that are available to investors today. That information is available publicly through Relmada media outlets and privately through word of mouth or via Relmada internal channels. However, regardless of the origin, that massive amount of Relmada data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relmada Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relmada Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relmada Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relmada Therapeutics alpha.

Relmada Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insiders Who Purchased US663.4k Of Relmada Therapeutics Stock May Not Have Expected 14 percent Tumble
09/06/2024
2
Acquisition by Kelly Paul Edward of 25000 shares of Relmada Therapeutics at 2.59 subject to Rule 16b-3
09/09/2024
3
Acquisition by Shenouda Maged of 21118 shares of Relmada Therapeutics at 2.73 subject to Rule 16b-3
09/10/2024
4
Acquisition by Shenouda Maged of 24120 shares of Relmada Therapeutics at 2.95 subject to Rule 16b-3
09/11/2024
5
Insider Spends US395k Buying More Shares In Relmada Therapeutics
09/13/2024
6
Relmada stock jumps as Jefferies upgrades
09/17/2024
7
Disposition of tradable shares by Ogorman Cedric of Relmada Therapeutics subject to Rule 16b-3
10/16/2024
8
Disposition of 13000 shares by Casamento Charles J of Relmada Therapeutics subject to Rule 16b-3
10/22/2024
9
Acquisition by Schmidt Eric Thomas of 57042 shares of Relmada Therapeutics subject to Rule 16b-3
10/28/2024
10
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
11/04/2024
11
Relmada Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Financial ...
11/08/2024
12
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
11/19/2024
13
Acquisition by Ence Chuck of 14500 shares of Relmada Therapeutics at 3.8657 subject to Rule 16b-3
11/20/2024

Complementary Tools for Relmada Stock analysis

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk